CRESCENT BIOPHARMA, INC.
corporate_fare Company Profile
CRESCENT BIOPHARMA, INC. (NASDAQ:CBIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for CBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-07-30, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for CBIO spans 10-Q, 8-K, SCHEDULE 13D/A, 424B5.
Recent high-impact activity:
- Crescent Biopharma Q2 Loss Narrows to $24.8M; Pro Forma Cash Hits $305M, Runway Into 2028
- Crescent Biopharma Extends Cash Runway to H2 2028 with Q2 2026 Results, Maps Out Multiple 2027 Data Catalysts
- Crescent Biopharma Posts $24.8M Q2 Loss, Cash Runway Extended to H2 2028; Key Data Readouts in 2027
- Fairmount Funds reveals $20M commitment in Crescent Biopharma's $125M offering, lifting its stake to 16.5%
- Crescent Biopharma Closes $143.7M Offering, Full Overallotment Exercised
Financial Snapshot
Short Interest & Short Volume
8.51 days to coverFINRA reported short interest of 3,407,158 shares in CBIO as of the September 15, 2026 settlement, a 7.4% increase from the prior period — about 8.5 days to cover at its recent average daily volume. On October 2, 2026, 74.9% of CBIO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CBIO, detected from its recent SEC filings · based on capital-structure filings through 2026-07-30.
Offering Priced at $14.50/Share · Net Proceeds of ~$115.9 Million
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →